Monograph
A02BA01 - Cimetidine |
Not porphyrinogenic |
NP |
Rationale
Only metabolised to a minor extent. Unspecific CYP-inhibitor (CYPs 2C9, 11B1, 1A2, 2C19, 2D6, 2E1, 3A4). To be observed: imidazole is an CYP 2E1 inducer! Several references consider it safe or probably safe. Also repeatedly used without porphyric side effects.
Chemical description
Imidazole histamine-receptor antagonist used in ventricular hyperacidity. Slightly (10-15 %) metabolized enzymatically to sulfdioxide. In large parts excreted unchanged in urine. Unspecific CYP-inhibitor which has been used in the treatment of the acute porphyric attack. MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-5: use with care South African list: use with care. French list: authorized. Merck Index: safe. Siepmann M et al. Cimetidine in treatment of acute intrmittent porphyria. Z Gastroenterol. 31:246, 1993: safe. D.Andersson: Frequently used without porphyric side effects. C.Andersson; patient reports: tolerated (n=2)
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Norway
Luxembourg© NAPOS 2024